Mechanisms for the prevention of gastrointestinal cancer: The role of prostaglandin E2

Michael G. Backlund, Jason R. Mann, Raymond N. DuBois

    Research output: Contribution to journalArticlepeer-review

    86 Scopus citations

    Abstract

    Carcinoma of the colon or rectum represents one of the most common malignancies worldwide with a higher prevalence in industrialized regions. Epidemiologic studies of individuals taking non-steroidal anti-inflammatory drugs (NSAIDs) have shown a significant reduction in colorectal cancer (CRC) mortality compared to those individuals not receiving these agents. NSAIDs inhibit the enzymatic activity of both isoforms of cyclooxygenase (COX-1 and COX-2), while COX-2-selective inhibitors have shown some efficacy in reducing polyp formation. COX-2-derived bioactive lipids, including the primary prostaglandin (PG) generated in colorectal tumors, PGE2, are known to stimulate cell migration, proliferation and tumor-associated neovascularization while inhibiting cell death. Here we briefly review the role of NSAIDs in preventing CRC, as well as the proposed mechanism by which a COX-2-derived PG, PGE2, promotes colon cancer.

    Original languageEnglish (US)
    Pages (from-to)28-32
    Number of pages5
    JournalOncology
    Volume69
    Issue numberSUPPL. 1
    DOIs
    StatePublished - Oct 18 2005

    Keywords

    • 15-Hydroxyprostaglandin dehydrogenase
    • Colorectal cancer
    • Cyclooxygenase 2
    • Prostaglandin E

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Mechanisms for the prevention of gastrointestinal cancer: The role of prostaglandin E<sub>2</sub>'. Together they form a unique fingerprint.

    Cite this